We are live on ! Find out more
SPC

Slate Path Capital Portfolio holdings

AUM $6.73B
1-Year Est. Return 95.97%
This Fund
S&P 500
This Quarter Est. Return
+10.93%
1 Year Est. Return
+95.97%
3 Year Est. Return
+272.8%
5 Year Est. Return
+330.15%
10 Year Est. Return
+4,591.92%
AUM
$1.95B
AUM Growth
+$44.3M
Cap. Flow
+$12.8M
Cap. Flow %
0.66%
Top 10 Hldgs %
58.84%
Holding
47
New
7
Increased
7
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
WE
WeWork Inc.
WE
+$91.8M
2
NOV icon
NOV
NOV
+$56.5M
3
RIG icon
Transocean
RIG
+$51M
4
GDXJ icon
VanEck Junior Gold Miners ETF
GDXJ
+$41.7M
5
OVV icon
Ovintiv
OVV
+$40.3M

Sector Composition

Rank Sector Weight
1 Energy 37.38%
2 Communication Services 23.49%
3 Materials 15.12%
4 Real Estate 8.55%
5 Financials 4.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CLF icon
26
Cleveland-Cliffs
CLF
$6.49B
$15.6M 0.8%
485,000
GLHAU
27
DELISTED
Glass Houses Acquisition Corp. Unit
GLHAU
$9.91M 0.51%
1,000,000
STNE icon
28
StoneCo
STNE
$2.67B
$8.72M 0.45%
+745,000
New +$9.73M
CYCN icon
29
Cyclerion Therapeutics
CYCN
$15.2M
$7.95M 0.41%
357,880
CUE icon
30
Cue Biopharma
CUE
$118M
$7.24M 0.37%
49,454
BLUA.U
31
DELISTED
BlueRiver Acquisition Corp. Units, each consisting of one Class A ordinary share, and one-third of a redeemable Warrant to acquire one Class A ordinary shares
BLUA.U
$5.93M 0.3%
600,000
PHICU
32
DELISTED
Population Health Investment Co., Inc. Unit
PHICU
$4.97M 0.25%
500,000
FVAM
33
DELISTED
5:01 Acquisition Corp
FVAM
$4.92M 0.25%
500,000
NEXI
34
DELISTED
NexImmune, Inc. Common Stock
NEXI
$3.89M 0.2%
37,000
EIGR
35
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.12M 0.11%
+8,500
New +$1.34M
IAG icon
36
IAMGOLD
IAG
$8.05B
$1.22M 0.06%
350,000
RNLX
37
DELISTED
Renalytix plc American Depositary Shares
RNLX
$1.21M 0.06%
175,214
KGC icon
38
Kinross Gold
KGC
$27.7B
$1.06M 0.05%
180,000
AUROW
39
Aurora Innovation Warrant
AUROW
$317M
$648K 0.03%
437,500
HIPO.WS
40
DELISTED
Hippo Holdings Inc. Redeemable warrants, each whole warrant exercisable for one twenty-fifth (1/25) share of Common Stock at an exercise price of $287.50 per full share
HIPO.WS
$119K 0.01%
350,000
BHIL.WS
41
DELISTED
Benson Hill, Inc. Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50
BHIL.WS
$113K 0.01%
250,000
LMACW
42
DELISTED
Liberty Media Acquisition Corporation Warrants
LMACW
$67K ﹤0.01%
100,000
BRDS.WS
43
DELISTED
Bird Global, Inc. Warrants each whole warrant exercisable to purchase 1/25th of a share of Class A Common Stock at an exercise price of $287.50 per share
BRDS.WS
$46K ﹤0.01%
120,000
CRK icon
44
Comstock Resources
CRK
$3.7B
-3,590,000
Closed -$29M
GDX icon
45
VanEck Gold Miners ETF
GDX
$22.5B
-3,250,000
Closed -$104M
MOS icon
46
The Mosaic Company
MOS
$7.19B
-3,310,000
Closed -$130M
DEN
47
DELISTED
Denbury Inc.
DEN
-250,000
Closed -$19.1M

Similar funds

Slate Path Capital's Q1 2022 Portfolio in Review

As of Q1 2022, Slate Path Capital held 47 positions worth $1.95B, up 2.3% from $1.91B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Slate Path Capital's Q1 2022 filing shows 7 new, 7 increased, 5 reduced and 4 closed positions. Its largest new stake was NOV: 3,225,000 shares worth $63.2M. The largest sale was The Mosaic Company, an estimated $130M.

By sector, the portfolio is most concentrated in Energy at 37% of assets, up from 25% a quarter earlier, followed by Communication Services and Materials.

  • Slate Path Capital's largest Q1 2022 buy was NOV: 3,225,000 shares worth $63.2M.
  • Slate Path Capital added most to WeWork Inc. in Q1 2022, an estimated $91.8M increase.
  • Slate Path Capital's biggest Q1 2022 reduction was Cheniere Energy, cutting an estimated $44M.
  • Slate Path Capital fully exited The Mosaic Company in Q1 2022, selling an estimated $130M.
  • Slate Path Capital's ten largest holdings make up 59% of its $1.95B portfolio in Q1 2022.
  • Slate Path Capital opened 7 new positions and closed 4 in Q1 2022.
  • Slate Path Capital's portfolio value rose 2.3% quarter-over-quarter to $1.95B.

Based on Slate Path Capital's 13F filing for Q1 2022, filed 16 May 2022.